Table 2.

Patient demographics

Dose Level	Patient number	Age	Gender	Diagnosis	Type of surgery	Number of CD-NSC doses	Best response
1	1	59	M	Glioblastoma	Resection	9	Progressiona
1	2	59	F	Glioblastoma	Resection	8	Stable disease
1	3	48	F	Glioblastoma	Biopsy	9	Stable disease
2	4	26	M	Glioblastoma	Resection	4	Progression
2	5	40	M	Anaplastic pleomorphic xanthoastrocytoma	Resection	4	Progression
2	6	64	M	Glioblastoma	Biopsy	3	Progression
3	7	65	F	Glioblastoma	Resection	2	Progression
3	8	57	M	Glioblastoma	Resection	2	Progression
3	9	54	M	Glioblastoma	Resection	4	Progression
4	10	51	M	Glioblastoma	Resection	3	Progression
4	11	71	M	Glioblastoma	Resection	3	Progression
4	12	58	M	Glioblastoma	Biopsy	4	Progression
4	13	58	M	Glioblastoma	Resection	1b	Not assessed
4	14	56	M	High grade glioma	Resection	10	Stable disease
4	15	45	M	Glioblastoma	Biopsy	3	Progression
4	16	69	M	Gliosarcoma	Resection	2	Not assessedc

^aThe changes on Patient 1’s first brain MRI after 8 weeks of study treatment were inconclusive, and since he was neurologically stable, he continued with study treatment. When the second brain MRI approximately 8 weeks later showed definite tumor progression, re-review of the first brain MRI determined that those initial changes were from tumor growing, and so best response for him was changed to progression.

^bPatient 13 received only one dose of CD-NSCs due to migration of the Rickham catheter tip into the lateral ventricle; therefore, the patient was taken off the study.

^cPatient 16 experienced a dose-limiting toxicity (grade 3 wound infection) 3 weeks after start of study treatment, requiring removal of the Rickham catheter. Since he did not continue study treatment and chose to enroll in a hospice program, no further imaging of his brain was performed.